EXELIXIS INC (EXEL) Stock Fundamental Analysis
USA - NASDAQ:EXEL - US30161Q1040 - Common Stock
40.81 USD
+0.01 (+0.02%)
41.25 USD
+0.44 (+1.08%)
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EXEL is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
EXEL has a better Return On Assets (22.49%) than 97.20% of its industry peers.
EXEL's Return On Equity of 29.62% is amongst the best of the industry. EXEL outperforms 97.39% of its industry peers.
Looking at the Return On Invested Capital, with a value of 25.22%, EXEL belongs to the top of the industry, outperforming 98.32% of the companies in the same industry.
EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is below the industry average of 15.48%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(25.22%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROIC | 25.22% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
The Profit Margin of EXEL (27.01%) is better than 96.08% of its industry peers.
In the last couple of years the Profit Margin of EXEL has declined.
EXEL has a Operating Margin of 33.71%. This is amongst the best in the industry. EXEL outperforms 97.57% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
With an excellent Gross Margin value of 96.59%, EXEL belongs to the best of the industry, outperforming 96.08% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
EXEL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 12.25 indicates that EXEL is not in any danger for bankruptcy at the moment.
EXEL has a Altman-Z score of 12.25. This is amongst the best in the industry. EXEL outperforms 85.26% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.25 |
ROIC/WACC2.88
WACC8.75%
2.3 Liquidity
A Current Ratio of 3.51 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.51) which is in line with its industry peers.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Quick ratio of 3.44. This is comparable to the rest of the industry: EXEL outperforms 41.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.49%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)18.49%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.04% yearly.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.30% on average per year.
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y22.04%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y10.3%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXEL is valuated rather expensively with a Price/Earnings ratio of 17.22.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 94.96% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.06, EXEL is valued a bit cheaper.
A Price/Forward Earnings ratio of 14.06 indicates a correct valuation of EXEL.
96.08% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 32.73. EXEL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.22 | ||
| Fwd PE | 14.06 |
4.2 Price Multiples
95.90% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
96.64% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.57 | ||
| EV/EBITDA | 12.24 |
4.3 Compensation for Growth
EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 26.07% in the coming years.
PEG (NY)0.58
PEG (5Y)1.36
EPS Next 2Y25.25%
EPS Next 3Y26.07%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
40.81
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner Change0.04%
Ins Owners2.23%
Ins Owner Change-2.57%
Market Cap10.99B
Revenue(TTM)2.17B
Net Income(TTM)602.30M
Analysts78.46
Price Target44.77 (9.7%)
Short Float %7.94%
Short Ratio7.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-0.95%
PT rev (3m)-3.25%
EPS NQ rev (1m)3.07%
EPS NQ rev (3m)2.11%
EPS NY rev (1m)-0.86%
EPS NY rev (3m)2.04%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.22 | ||
| Fwd PE | 14.06 | ||
| P/S | 4.93 | ||
| P/FCF | 14.57 | ||
| P/OCF | 14.23 | ||
| P/B | 5.4 | ||
| P/tB | 5.58 | ||
| EV/EBITDA | 12.24 |
EPS(TTM)2.37
EY5.81%
EPS(NY)2.9
Fwd EY7.11%
FCF(TTM)2.8
FCFY6.86%
OCF(TTM)2.87
OCFY7.03%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.58
PEG (5Y)1.36
Graham Number20.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROCE | 32.1% | ||
| ROIC | 25.22% | ||
| ROICexc | 38.09% | ||
| ROICexgc | 39.72% | ||
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% | ||
| FCFM | 33.81% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 60.32% | ||
| Cap/Sales | 0.81% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.79% | ||
| Profit Quality | 125.2% | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 12.25 |
F-Score8
WACC8.75%
ROIC/WACC2.88
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y22.04%
Revenue 1Y (TTM)18.49%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y10.3%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 17.22 and the Price/Book (PB) ratio is 5.4.